Compare Adobe Systems Inc (ADBE) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adobe Systems Inc vs Merck & Co., Inc. — how do they compare? Adobe Systems Inc trades at $220.51 (market cap $88.06B), while Merck & Co., Inc. trades at $126.01 (market cap $318.26B). The key difference: Merck & Co., Inc. is far larger — about 3.6× Adobe Systems Inc's market cap, and Merck & Co., Inc. pays a 2.64% dividend while Adobe Systems Inc pays none. Which is the better fit depends on your goals.
| ADBE | MRK | |
|---|---|---|
Market Cap | $88.06B | $318.26B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $382.24 | $129.52 |
52-Week Low | $193.41 | $77.60 |
Enterprise Value | $89.50B | $361.68B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe Inc. (ADBE) trades at $221.01, up 1.35% on the day, with strong fundamentals including a P/E of 12.67 and net income margin of 28.69%. Recent earnings beats in Q3 2025 through Q1 2026 highlight operational strength, while technical indicators show a bullish overall signal despite some overbought RSI readings. The stock faces headwinds from AI competition concerns and a recent 52-week low, but institutional buying activity and a consensus price target of $246.75 suggest underlying confidence.
The outlook for ADBE is cautiously optimistic, with revenue growth and robust cash flow supporting valuation, but investor sentiment is mixed due to AI disruption fears and CEO transition. Near-term resistance at $224 and support at $218 will be key for price direction, with earnings execution and competitive response to AI being critical catalysts.
Merck (MRK) trades at $126.00, down 0.62% today, with a bullish technical outlook supported by moving averages and strong institutional buying. The company reported solid earnings beats in recent quarters, with Q1 2026 loss narrower than expected. Revenue reached $65.01B in 2025, with net income margin improving to 28.07%. Recent acquisition of Terns Pharmaceuticals for approximately $6.7 billion aims to bolster its oncology pipeline, reflecting strategic growth initiatives.
Outlook remains positive with a consensus price target of $139.33, implying 11% upside, supported by 67.6% analyst buy ratings. Risks include rising debt-to-asset ratio to 36.06% in 2025 and projected net cash flow decline to -$3.3B in 2026. Competitive pressures in pharma and macroeconomic uncertainties could challenge growth, but strong profitability and dividend yield offer defensive appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
